Results obtained by Oncobiomed scientists have been published through papers in high impact scientific journals, like the British Journal of Cancer, Journal of Clinical Oncology and Cancer Immunology Immunotherapy, among others.
Scientific Publications
2020
Journal of Immunotherapy of Cancer
A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth.
2019
Journal of Immunology Research
Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses In Vitro.
2018
Journal of Immunology Research
Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy.
2018
Oncotarget
Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy.
2018
Cancer immunology, immunotherapy
Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer.
2013
Cancer Immunology and Immunotherapy
Immunological and Clinical Outcomes of DC-Vaccinated Melanoma Patients Are Associated with Increased Th1/Th17 and Reduced Th3 Cytokine Responses.
2013
British Journal of Cancer
Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients.
2013
Biological Research
TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer.
2012
Cancer Immunology and Immunotherapy
Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients.
2011
Clinical Cancer Research
Heat-Shock Induction of Tumor-Derived Danger Signals Mediate Rapid Monocyte Differentiation into Clinically Effective Dendritic Cells.
2009
Journal of Clinical Oncology
Prolonged Survival of Dendritic Cell–Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor B-Expressing T Cells.
2007
Cytokine Growth Factor
Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape.
2006
Immunobiology
The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
2005
Clinical and Experimental Immunology
Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
Research Projects
Project: Effective immunotherapy for Alzheimer disease treatment: pre-clinical trial. 2020
Institution: University of Chile
Associated company: Oncobiomed
Director: Dr. María Isabel Behrens (PhD)
Funding: FONDEF
Project: Translational research for the development of a generic cell vaccine (TRIMELVax) against advanced malignant melanoma. 2020
Institution: University of Chile
Associated company: Oncobiomed
Director: Dr. Mercedes Lopez (PhD)
Funding: FONDEF
Project: TAPCells® Technology Transfer to Brazil. 2020
Associated Companies: Grupo Sao Lucas, LifeTech, Oncobiomed
Director: Biotechnology Engineer, Cristián Pereda
Funding: Private
Project: Optimisation of the Manufacturing, Preservation and Functional Stability of immunotherapeutic oncology products TRIMEL. 2019
Company: Oncobiomed
Performer: Dr. Andrés Tittarelli (PhD)
Funding: ANID
Project: Design and pre-contract for provision of processing of bio-produced batches of lysates for research use and mass production of Trimel. 2019
Performer: Cassará Laboratory
Director: Andrés Tittarelli (PhD)
Funding: Oncobiomed
Project: Identification of immunological and drug resistance biomarkers in tumours and peripheral blood for prognosis and monitoring of patients with gallbladder cancer. 2019
Institution: University of Valdivia
Director: Dr. Claudia Quezada (PhD)
Oncobiomed: Ad honorem support in technology diffusion
Funding: GORE Los Ríos, Innovation for Competitiveness Fund (FIC, in Spanish)
Project: Technology against melanoma based on direct administration of immunogenic conditioned tumour lysates in combination with natural adjuvants. 2019
Director: Biotechnology Engineer Cristián Pereda
Funding: Know Hub Ignition Fund
Project: Thermovax Validation and Technology Packaging for the Treatment of Oncological Pathologies. 2017
Institution: Fraunhofer Chile
Beneficiary: Oncobiomed
Director: Dr. Carlos Saffie (PhD)
Funding: CORFO
Project: TAPCells® to Global Market. 2013
Beneficiary: Oncobiomed
Director: Biotechnology Engineer Cristián Pereda
Funding: CORFO Innova
Project: Characterisation and Production of Tumour Antigenic Compounds for Ex-vivo Activation of Autologous Cells for Potential Use in Cancer Cellular Immunotherapy. 2012
Institution: University of Chile
Associated company: Oncobiomed
Director: Dr. Flavio Salazar (PhD)
Funding: FONDEF
Project: Economic Valorisation of TAPCells® technology and design of a business model for its transfer. 2010
Institution: University of Chile
Associated Company: Oncobiomed
Director: Dr. Flavio Salazar (PhD)
Funding: FONDEF
Project: Characterisation of a melanoma lysate (TRIMEL) and its effect on maturation and differentiation of monocyte-derived dendritic cells from cancer patients for cellular immunotherapy. 2007
Institution: University of Chile
Associated Company: Oncobiomed
Directors: Dr. Mercedes López (PhD), Dr. Flavio Salazar (PhD)
Funding: FONDEF
Project: Research and Development of optimised biological therapies for urological tumours. 2005
Institution: University of Chile
Associated Company: Oncobiomed
Director: Dr. Flavio Salazar (PhD)
Funding: FONDEF
Project: Research and Development of Biological vaccines for Oncology Immunotherapy. 2003
Institution: University of Chile
Associated Company: Oncobiomed
Director: Dr. Flavio Salazar (PhD)
Funding: FONDEF